Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) Other Operating Expenses (2022 - 2025)

Historic Other Operating Expenses for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $6.8 million.

  • Century Therapeutics' Other Operating Expenses rose 75499.37% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.9 million, marking a year-over-year decrease of 2152.7%. This contributed to the annual value of $6.6 million for FY2024, which is 6915.98% down from last year.
  • As of Q3 2025, Century Therapeutics' Other Operating Expenses stood at $6.8 million, which was up 75499.37% from $4.2 million recorded in Q4 2024.
  • Over the past 5 years, Century Therapeutics' Other Operating Expenses peaked at $13.1 million during Q4 2023, and registered a low of $99000.0 during Q2 2023.
  • Over the past 4 years, Century Therapeutics' median Other Operating Expenses value was $4.2 million (recorded in 2024), while the average stood at $5.0 million.
  • As far as peak fluctuations go, Century Therapeutics' Other Operating Expenses plummeted by 6825.41% in 2024, and later skyrocketed by 75499.37% in 2025.
  • Quarter analysis of 4 years shows Century Therapeutics' Other Operating Expenses stood at $10.0 million in 2022, then surged by 31.45% to $13.1 million in 2023, then crashed by 68.25% to $4.2 million in 2024, then surged by 62.07% to $6.8 million in 2025.
  • Its Other Operating Expenses was $6.8 million in Q3 2025, compared to $4.2 million in Q4 2024 and $791000.0 in Q3 2024.